Spero Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq (United States) under the ticker SPRO. Headquartered in Cambridge, Massachusetts, United States, the company was founded in 2013 and has built its strategy around unmet medical needs in multidrug-resistant (MDR) bacterial infections and selected rare diseases. From an equity research perspective, Spero is best viewed as a niche, catalyst-driven biotech rather than a commercial-stage pharmaceutical company: valuation is primarily tied to clinical readouts, regulatory milestones, licensing economics, and balance-sheet durability. ([sperotherapeutics.com](https://www.sperotherapeutics.com/about-us?utm_source=openai)) The lead asset is tebipenem HBr, an investigational oral carbapenem being developed for complicated urinary tract infection (cUTI), including pyelonephritis. Spero states that it granted GSK an exclusive license to commercialize tebipenem HBr in all territories except certain Asian markets, which means the program is strategically important even though Spero is not the primary commercial operator. The pipeline also includes SPR720, an oral candidate for nontuberculous mycobacterial pulmonary disease (NTM-PD), but that development program has been suspended after a phase 2a analysis failed to support the target profile. SPR206, another anti-infective asset aimed at MDR Gram-negative infections, remains part of the broader scientific franchise but is not the company’s core near-term value driver. ([sperotherapeutics.com](https://www.sperotherapeutics.com/pipeline?utm_source=openai)) In competitive terms, Spero occupies a specialized position in anti-infectives, focused on therapeutic areas where oral treatment options remain limited and intravenous care is still the standard of care. The strategic appeal of tebipenem HBr is that it could become the first oral carbapenem available in the United States if approved, potentially changing the treatment pathway for cUTI patients by enabling earlier discharge or avoiding hospitalization altogether. Spero does not compete on scale against large-cap pharma; instead, it competes on differentiation, clinical proof-of-concept, and regulatory execution. ([sperotherapeutics.com](https://www.sperotherapeutics.com/pipeline?utm_source=openai)) Recent developments have centered on tebipenem HBr. In May 2025, Spero and GSK announced that the pivotal phase 3 PIVOT-PO trial met its primary endpoint and would stop early for efficacy. GSK then submitted an NDA resubmission to the FDA in December 2025, and Spero’s 2025 annual report, published in 2026, stated that the FDA accepted that resubmission. For investors, SPRO is therefore a high-beta healthcare name on Nasdaq in the United States, with the investment case hinging mainly on the regulatory path for tebipenem HBr, partnership economics with GSK, and the company’s ability to preserve financial flexibility while it evaluates its next pipeline steps. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee/?utm_source=openai))